论文部分内容阅读
目的 :评价非小细胞肺癌 ( NSCL C)术前化疗后的疗效和观察其病理学的表现。方法 :随机选择 2 2例 NSCL C病人 ,其中 11例术前行 MVP方案化疗 1～ 2个周期 ,外科手术切除标本进行光镜和电镜的观察并评定其疗效 ,与临床评价进行比较。结果 :化疗组有不同程度的病理变化 ,原发灶的肿瘤细胞显示不同程度的变性和坏死 ,化疗反应率 、 和 级分别为 0 .0 %、63.6%和 36.4 % ,总有效率 ( 级和 级 )为 63.6% ( 7/11) ,低分化肿瘤患者的有效率占总有效率的 85.7% ( 6/7) ,临床评价与病理学评价的符合率为 72 .7% ,两种评价方法之间无显著性差异 ( P>0 .0 5) ,在非化疗组没有明显的肿瘤细胞的消失。结论 :对非小细胞肺癌术前行 MVP方案辅助化疗与单纯手术相比有更好的治疗效果 ,伴有纤维化的变性和坏死是原发灶化疗后的主要表现形式 ,超微结构的观察可有效的弥补光镜观察的不足
Objectives: To evaluate the efficacy of postoperative chemotherapy for non-small cell lung cancer (NSCL C) and to observe its pathological appearance. METHODS: Twenty-two patients with NSCL C were randomly selected. Among them, 11 patients underwent MVP regimen chemotherapy 1 to 2 cycles before surgery. Surgical resection specimens were observed by light and electron microscopy and assessed for efficacy, and compared with clinical evaluation. Results: The chemotherapy group had different degree of pathological changes. The tumor cells of the primary tumor showed varying degrees of degeneration and necrosis. The chemotherapy response rate and grade were 0.0%, 63.6%, and 36.4%, respectively, and the total effective rate (levels (Level) was 63.6% (7/11). The effective rate of poorly differentiated tumors was 85.7% (6/7) of the total effective rate. The rate of coincidence between clinical evaluation and pathological evaluation was 72.7%. There was no significant difference between the two groups (P>0.05). There was no obvious disappearance of tumor cells in the non-chemotherapy group. Conclusion: The treatment of non-small cell lung cancer with preoperative MVP adjuvant chemotherapy is better than surgery alone. The degeneration and necrosis associated with fibrosis is the main manifestation after primary tumor chemotherapy. Ultrastructure observation Can effectively compensate for the lack of light microscope observation